Format
Sort by
Items per page

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 320

1.

Proteasome inhibitors for the treatment of multiple myeloma.

Scalzulli E, Grammatico S, Vozella F, Petrucci MT.

Expert Opin Pharmacother. 2018 Mar;19(4):375-386. doi: 10.1080/14656566.2018.1441287. Epub 2018 Feb 26. Review.

PMID:
29478351
2.

Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.

Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X.

Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15.

PMID:
29446103
3.

Triplet vs. doublet drug regimens for managing multiple myeloma.

Offidani M, Corvatta L, Gentili S.

Expert Opin Pharmacother. 2018 Feb;19(2):137-149. doi: 10.1080/14656566.2017.1418856. Epub 2017 Dec 21. Review.

PMID:
29265901
4.

Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.

Takahashi K, Inukai T, Imamura T, Yano M, Tomoyasu C, Lucas DM, Nemoto A, Sato H, Huang M, Abe M, Kagami K, Shinohara T, Watanabe A, Somazu S, Oshiro H, Akahane K, Goi K, Kikuchi J, Furukawa Y, Goto H, Minegishi M, Iwamoto S, Sugita K.

PLoS One. 2017 Dec 13;12(12):e0188680. doi: 10.1371/journal.pone.0188680. eCollection 2017.

5.

Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.

Xu W, Sun X, Wang B, Guo H.

Ann Hematol. 2018 Feb;97(2):299-307. doi: 10.1007/s00277-017-3173-9. Epub 2017 Nov 20.

PMID:
29159498
6.

An overview of the role of carfilzomib in the treatment of multiple myeloma.

Ziogas DC, Terpos E, Kastritis E, Dimopoulos MA.

Expert Opin Pharmacother. 2017 Dec;18(17):1883-1897. doi: 10.1080/14656566.2017.1404575. Epub 2017 Nov 20. Review.

PMID:
29134824
7.

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.

Pelligra CG, Parikh K, Guo S, Chandler C, Mouro J, Abouzaid S, Ailawadhi S.

Clin Ther. 2017 Oct;39(10):1986-2005.e5. doi: 10.1016/j.clinthera.2017.08.010. Epub 2017 Sep 28.

8.

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity.

Hasinoff BB, Patel D.

Arch Biochem Biophys. 2017 Nov 1;633:23-28. doi: 10.1016/j.abb.2017.09.003. Epub 2017 Sep 5.

PMID:
28887129
9.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P.

Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.

PMID:
28843768
10.

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.

Br J Haematol. 2017 Oct;179(1):36-49. doi: 10.1111/bjh.14807. Epub 2017 Jul 2.

PMID:
28670693
11.

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.

Chen-Scarabelli C, Corsetti G, Pasini E, Dioguardi FS, Sahni G, Narula J, Gavazzoni M, Patel H, Saravolatz L, Knight R, Raddino R, Scarabelli TM.

EBioMedicine. 2017 Jul;21:206-212. doi: 10.1016/j.ebiom.2017.05.024. Epub 2017 May 23.

12.

Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.

Moreau P, de Wit E.

Br J Haematol. 2017 Oct;179(2):198-218. doi: 10.1111/bjh.14780. Epub 2017 May 30. Review.

PMID:
28556890
13.

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.

Jakubowiak AJ, DeCara JM, Mezzi K.

Hematology. 2017 Dec;22(10):585-591. doi: 10.1080/10245332.2017.1328165. Epub 2017 May 25.

PMID:
28545322
14.

Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.

Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, Vij R, Salama NN, Azab AK.

Leuk Lymphoma. 2017 Dec;58(12):2916-2925. doi: 10.1080/10428194.2017.1319052. Epub 2017 May 16.

PMID:
28509582
15.

Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.

Schäfer J, Welti L, Seckinger A, Burhenne J, Theile D, Weiss J.

Cancer Chemother Pharmacol. 2017 Jul;80(1):71-79. doi: 10.1007/s00280-017-3335-4. Epub 2017 May 12.

PMID:
28500557
16.

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, Landgren O, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):217-221. doi: 10.1007/s00280-017-3323-8. Epub 2017 May 9.

PMID:
28488026
17.

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.

Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H.

Leukemia. 2017 Dec;31(12):2630-2641. doi: 10.1038/leu.2017.122. Epub 2017 Apr 25.

18.

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.

Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A.

Blood Cancer J. 2017 Apr 21;7(4):e554. doi: 10.1038/bcj.2017.31.

19.

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.

Quach H, White D, Spencer A, Ho PJ, Bhutani D, White M, Inamdar S, Morris C, Ou Y, Gyger M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1067-1076. doi: 10.1007/s00280-017-3287-8. Epub 2017 Apr 19.

20.

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.

Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG.

Oncotarget. 2017 May 30;8(22):35863-35876. doi: 10.18632/oncotarget.16262.

Supplemental Content

Support Center